Phase IIb Protocol 011: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction in Treatment-Naive Patients Demonstrates Very Low HIV-1 RNA Levels in Patients With Wk 48 Protocol-Defined Virologic Failure

July 6-10, 2020; Virtual
Among 5 patients with protocol-defined virologic failure at Week 48 in this study, none experienced HIV-1 RNA > 200 copies/mL.
Format: Microsoft PowerPoint (.ppt)
File Size: 209 KB
Released: July 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

Released: August 2, 2022

Expert insights on new, emerging, and potential future long-acting antiretroviral agents for HIV treatment and prevention, from Clinical Care Options (CCO)

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings